Literature DB >> 6871885

Phase I study of acivicin in patients with advanced cancer.

K S Sridhar, T Ohnuma, A P Chahinian, J F Holland.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6871885

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  6 in total

1.  A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.

Authors:  S Baruchel; M Bernstein; V M Whitehead; S Devine; B Bell; R Dubowy; H Grier; C Kretschmar; A M Langevin; T Vietti
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  Phase I-II trial of acivicin in adult acute leukemia.

Authors:  B L Powell; J B Craig; R L Capizzi; F Richards
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

3.  Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  E A Eisenhauer; J A Maroun; A L Fields; P L Walde
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

4.  Effect of inhibition of gamma-glutamyltranspeptidase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasma.

Authors:  K E Hill; D D Von Hoff; R F Burk
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; P J DiSaia; H J Buchsbaum
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.

Authors:  R H Earhart; J D Khandekar; D Faraggi; R A Schinella; T E Davis
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.